Amygdala Neurosciences Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $5.6M
Latest Deal Amount
  • Investors
  • 2

Amygdala Neurosciences General Information

Description

Operator of a biopharmaceutical firm intended to focus on the large and growing unmet need associated with substance use disorders. The company's technology uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated craving without changes to basal dopamine, enabling patients to quit and get rid of their addiction to drugs, alcohol, and smoking.

Contact Information

Website
www.amygns.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 5214F Diamond Heights Boulevard
  • Suite 151
  • San Francisco, CA 94131
  • United States
+1 (650) 000-0000

Amygdala Neurosciences Timeline

2019202020212022
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amygdala Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Seed Round 28-Apr-2021 $5.6M 000.00 000.00 Completed Generating Revenue
5. Grant 21-Oct-2019 00.000 00.000 Completed Generating Revenue
4. Grant 19-Sep-2018 000.00 00.000 Completed Generating Revenue
3. Seed Round 19-May-2017 00.000 00.000 000.00 Completed Generating Revenue
2. Seed Round 10-Feb-2017 $2M $3.45M 000.00 Completed Generating Revenue
1. Seed Round 10-Apr-2015 $1.45M $1.45M 000 Completed Generating Revenue
To view Amygdala Neurosciences’s complete valuation and funding history, request access »

Amygdala Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-4 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed-3 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Seed-2 4,340,673 $0.000100 $0.03 $0.55 $0.55 1x $0.5 11.97%
Seed-1 5,307,464 $0.000100 $0.02 $0.27 $0.27 1x $0.27 13.24%
To view Amygdala Neurosciences’s complete cap table history, request access »

Amygdala Neurosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical firm intended to focus on the large and growing unmet need associated with substance use
Drug Discovery
San Francisco, CA
000.00
00.00 0000-00-00
000000000 000.00

00000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000000
New York, NY
000000000000

0000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Framingham, MA
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amygdala Neurosciences Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidence Therapeutics Accelerator/Incubator Backed New York, NY 000000000000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
00000 000000000000 Formerly VC-backed Grand Rapids, MI 0 0000 000000&0 0000
0000000 Formerly VC-backed Calabasas, CA 00 0000 000000&0 0000
0000000 Venture Capital-Backed Singapore, Singapore 00 00000 00000 00000
You’re viewing 5 of 17 competitors. Get the full list »

Amygdala Neurosciences Patents

Amygdala Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3863424-A1 Addiction treatment of an alcohol-consuming patient population Pending 12-Oct-2018 0000000000
US-20210220376-A1 Addiction treatment of an alcohol-consuming patient population Pending 12-Oct-2018 0000000000
US-20210145844-A1 Combination therapy for nicotine addiction Pending 27-Jul-2018 0000000000
EP-3829562-A1 Combination therapy for nicotine addiction Pending 27-Jul-2018 0000000000
EP-3697415-A4 Combination therapy for preventing addiction Pending 16-Oct-2017 A61K31/4418 0
To view Amygdala Neurosciences’s complete patent history, request access »

Amygdala Neurosciences Executive Team (6)

Name Title Board Seat Contact Info
Brent Blackburn Ph.D Co-Founder, Chief Executive Officer & Chief Development Officer
Adrienne MacMillan Co-Founder & Chief Financial Officer
Ivan Diamond Ph.D Co-Founder, Board Member & Chief Scientific Officer
Louis Lange MD Co-Founder & Executive Chairman
Peter Strumph Co-Founder & Board Member
You’re viewing 5 of 6 executive team members. Get the full list »

Amygdala Neurosciences Board Members (6)

Name Representing Role Since
Howard Jaffe Amygdala Neurosciences Board Member 000 0000
Ivan Diamond Ph.D Amygdala Neurosciences Co-Founder, Board Member & Chief Scientific Officer 000 0000
Louis Lange MD Amygdala Neurosciences Co-Founder & Executive Chairman 000 0000
Mack Mitchell MD Self Chief Medical Officer & Board Member 000 0000
Peter Strumph Amygdala Neurosciences Co-Founder & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Amygdala Neurosciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Amygdala Neurosciences’s complete investors history, request access »

Amygdala Neurosciences Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 16-Feb-2017 000000000 Buildings and Property 00000 000
To view Amygdala Neurosciences’s complete investments history, request access »